{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:21:58Z","timestamp":1788430918962,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy that may follow infectious triggers and can progress to severe weakness, cranial nerve involvement, autonomic dysfunction, and respiratory failure. Cytomegalovirus (CMV)-associated GBS is often linked to a more severe clinical course. Although intravenous immunoglobulin (IVIG) and plasma exchange are established first-line treatments, management becomes challenging when patients deteriorate after initial therapy, particularly when distinguishing poor prognosis from treatment-related fluctuation (TRF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 42-year-old woman who developed progressive paresthesias, diffuse pain, gait disturbance, areflexia, facial involvement, dysphagia, dysarthria, autonomic dysfunction, and later respiratory failure. Cerebrospinal fluid analysis showed albuminocytologic dissociation, electrodiagnostic studies supported acute polyradiculoneuropathy, and MRI demonstrated contrast enhancement of the facial nerve roots and cauda equina. Serum testing revealed CMV IgM positivity with detectable CMV DNA, consistent with CMV-associated GBS. The patient received IVIG and ganciclovir. After initial stabilization following the first IVIG course, she experienced sudden respiratory deterioration requiring intubation. Given the temporal pattern of stabilization followed by worsening, the episode was interpreted as TRF occurring in a patient with otherwise poor prognostic features. A second IVIG cycle was administered, followed by gradual respiratory and neurological improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case illustrates the clinical difficulty of deciding whether repeated immunotherapy is justified in severe GBS. Current evidence discourages routine second IVIG courses in patients with poor prognosis who fail to respond; however, this recommendation does not necessarily apply to TRF, where renewed immunotherapy may be considered. In this patient, post-IVIG stabilization followed by acute deterioration supported the interpretation of TRF; persistent CMV viremia was considered a possible marker of ongoing immune stimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CMV-associated GBS may follow a severe and fluctuating course. Careful distinction between poor prognosis, nonresponse, and treatment-related fluctuation is essential because it directly influences therapeutic decision-making. Close monitoring, individualized immunotherapy, intensive supportive care, and early rehabilitation remain central to optimizing outcomes in severe GBS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1889220","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:08:45Z","timestamp":1788430125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Differentiating poor prognosis from treatment-related fluctuations in Guillain-Barr\u00e9 syndrome for repeating immunoglobulin treatment: an illustrative case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessio","family":"D\u2019Elia","sequence":"first","affiliation":[{"name":"Neurology Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Mascia","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Salento","place":["Lecce, Italy"]},{"name":"Anesthesiology and Intensive Care Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Gregorio","family":"Giaccari","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Salento","place":["Lecce, Italy"]},{"name":"Anesthesiology and Intensive Care Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Comanducci","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Maistrello","sequence":"additional","affiliation":[{"name":"IRCCS Fondazione Don Carlo Gnocchi","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Lozupone","sequence":"additional","affiliation":[{"name":"Neuroradiology Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica Santo","family":"Sabato","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Bianco","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Lucchese","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]},{"name":"Department of Experimental Medicine, University of Salento","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16365","article-title":"Guillain\u2013Barr\u00e9 syndrome: a comprehensive review","volume":"31","author":"Bellanti","year":"2024","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1062261","article-title":"Guillain-Barr\u00e9 syndrome","volume":"28","author":"Burns","year":"2008","journal-title":"Semin Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir074","article-title":"Guillain\u2013Barr\u00e9 Syndrome following Primary Cytomegalovirus Infection: a prospective cohort study","volume":"52","author":"Orlikowski","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100468","DOI":"10.1016\/j.ensci.2023.100468","article-title":"Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis","volume":"31","author":"Zaki","year":"2023","journal-title":"eNeurologicalSci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X-ANP-2021-0226","article-title":"Treatment-related fluctuations in Guillain-Barr\u00e9 syndrome: clinical features and predictors of recurrence","volume":"80","author":"Alessandro","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12883-020-01796-z","article-title":"Clinical features of Guillain-Barr\u00e9 syndrome patients with elevated serum creatine kinase levels","volume":"20","author":"Hosokawa","year":"2020","journal-title":"BMC Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18700\/jnc.210011","article-title":"Flaccid quadriparesis with raised creatine kinase in Guillain-Barr\u00e9 syndrome: a case report with review of literature","volume":"14","author":"Mahesh","year":"2021","journal-title":"J Neurocrit Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJM199610313351814","article-title":"Ganciclovir-induced psychosis","volume":"335","author":"Hansen","year":"1996","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1712202","article-title":"Plasma exchange following immunoglobulins for Guillain-Barr\u00e9-Syndrome: a persisting problematic practice","volume":"16","author":"Lucchese","year":"2026","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102993","article-title":"Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy","volume":"59","author":"Balagholi","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13054-020-03070-7","article-title":"First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19","volume":"24","author":"Stahl","year":"2020","journal-title":"Crit Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000167549.09664.b8","article-title":"Distinguishing acute-onset CIDP from Guillain-Barr\u00e9 syndrome with treatment related fluctuations","volume":"65","author":"Ruts","year":"2005","journal-title":"Neurology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.11.957","article-title":"Treatment related fluctuations in Guillain-Barr\u00e9 syndrome after high-dose immunoglobulins or plasma-exchange","volume":"54","author":"Kleyweg","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4103\/aian.AIAN_242_17","article-title":"Treatment-related fluctuations in Guillain Barr\u00e9 syndrome and the conundrum of additional cycles of plasmapheresis","volume":"20","author":"Ramakrishnan","year":"2017","journal-title":"Ann Indian Acad Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:08:46Z","timestamp":1788430126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1889220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1889220"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1889220","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1889220"}}